1,6-二甲基-1,3-二氢-2H-苯并咪唑-2-酮 | 15965-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,6-二甲基-1,3-二氢-2H-苯并咪唑-2-酮
• 英文名称: 1,6-Dimethylbenzimidazolon
• 英文别名: 1,6-Dimethyl-benzimidazolon-(2)；1,6-dimethyl-1,3-dihydro-benzoimidazol-2-one；1,6-Dimethyl-1H-benzo[d]imidazol-2(3H)-one；3,5-dimethyl-1H-benzimidazol-2-one
• CAS: 15965-68-1
• 化学式: C₉H₁₀N₂O
• mdl: MFCD18800925
• 分子量: 162.191
• InChiKey: GTDHFKHSNKAMNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF<br/>[FR] COMPOSÉS QUINAZOLINONES ET LEURS DÉRIVÉS
  申请人：AMGEN INC

  公开号：WO2014036022A1

  公开（公告）日：2014-03-06

  Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物是坦克酶的有用抑制剂。公式I的化合物具有以下结构：其中变量的定义在此提供。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Yamashita Hiroshi

  公开号：US20090264404A1

  公开（公告）日：2009-10-22

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，其化学式为（1）：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香族基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的谱，包括中枢神经系统障碍，无副作用且安全性高。
• UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS
  申请人：ALLEN Jennifer R.

  公开号：US20110306587A1

  公开（公告）日：2011-12-15

  Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物，如本说明书中所定义的，含有它们的组合物以及制备这种化合物的方法。本文还提供了治疗可通过抑制PDE10治疗的疾病或疾病的方法，例如肥胖症，亨廷顿病，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症等。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。